Cynthia Hawkins

List of Publications by Citations

239 papers	23,218 citations	78 h-index	151 g-index
266 ext. papers	29,335 ext. citations	6.2 avg, IF	6.64 L-index

#	Paper	IF	Citations
239	Identification of human brain tumour initiating cells. *Nature*, **2004**, 432, 396-401	50.4	5869
238	Identification of a cancer stem cell in human brain tumors. *Cancer Research*, **2003**, 63, 5821-8	10.1	3368
237	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro-Oncology* , **2021**, 23, 1231-1251	1	708
236	K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. *Acta Neuropathologica*, **2012**, 124, 439-47	14.3	629
235	Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. *Cell*, **2012**, 148, 59-71	56.2	600
234	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. *Cancer Cell*, **2017**, 32, 520-537.e5	24.3	423
233	Comprehensive Analysis of Hypermutation in Human Cancer. *Cell*, **2017**, 171, 1042-1056.e10	56.2	417
232	Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. *Nature Genetics*, **2014**, 46, 451-6	36.3	411
231	International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. *Brain Pathology*, **2014**, 24, 429-35	6	408
230	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. *Nature Reviews Cancer*, **2014**, 14, 92-107	31.3	383
229	Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. *Nature Medicine*, **2015**, 21, 555-9	50.5	319
228	Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. *Nature Genetics*, **2015**, 47, 257-62	36.3	253
227	Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. *Journal of Clinical Oncology*, **2010**, 28, 1337-44	2.2	251
226	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. *Lancet Oncology, The*, **2013**, 14, 1200-7	21.7	226
225	Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. *Acta Neuropathologica*, **2014**, 128, 573-81	14.3	203
224	cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. *Brain Pathology*, **2020**, 30, 844-856	6	196
223	BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. *Clinical Cancer Research*, **2011**, 17, 4790-8	12.9	178

222	Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. *Lancet Oncology, The*, **2013**, 14, 534-42	21.7	169
221	Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. *Journal of Clinical Oncology*, **2012**, 30, 1358-63	2.2	158
220	Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 8188-93	11.5	156
219	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. *Nature Genetics*, **2016**, 48, 273-82	36.3	154
218	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. *Journal of Clinical Oncology*, **2017**, 35, 2934-2941	2.2	153
217	Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. *European Journal of Cancer*, **2014**, 50, 987-96	7.5	149
216	TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. *Journal of Clinical Oncology*, **2010**, 28, 1995-2001	2.2	144
215	Pediatric high-grade glioma: biologically and clinically in need of new thinking. *Neuro-Oncology*, **2017**, 19, 153-161	1	125
214	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. *Journal of Clinical Oncology*, **2018**, 36, 1963-1972	2.2	125
213	Study of the biodistribution of fluorescein in glioma-infiltrated mouse brain and histopathological correlation of intraoperative findings in high-grade gliomas resected under fluorescein fluorescence guidance. *Journal of Neurosurgery*, **2015**, 122, 1360-9	3.2	119
212	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. *Acta Neuropathologica*, **2017**, 134, 705-714	14.3	114
211	Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. *Science Translational Medicine*, **2016**, 8, 366ra161	17.5	109
210	Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. *Journal of Clinical Investigation*, **2012**, 122, 253-66	15.9	108
209	Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. *Clinical Cancer Research*, **2011**, 17, 4650-60	12.9	103
208	Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. *Journal of Clinical Oncology*, **2006**, 24, 1522-8	2.2	100
207	Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. *Nature Communications*, **2019**, 10, 4343	17.4	95
206	Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics. *Acta Neuropathologica Communications*, **2016**, 4, 1	7.3	93
205	cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF mutation. *Acta Neuropathologica*, **2019**, 137, 683-687	14.3	92

204	Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. *Cancer Cell*, **2020**, 37, 569-583.e5	24.3	92
203	Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients?. *Neuro-Oncology*, **2016**, 18, 291-7	1	86
202	PINK1 Is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma. *Cancer Research*, **2016**, 76, 4708-19	10.1	80
201	DIPG-22. GENETIC MODELING IMPLICATES RAS AND MYC AS KEY EPIGENETICALLY ACTIVATED TRANSCRIPTIONAL TARGETS OF H3K27M-DRIVEN CANCER. *Neuro-Oncology*, **2019**, 21, ii73-ii73	1	78
200	DIPG-35. OPEN DIPG INITIATIVE: A PLATFORM FOR ACCELERATING DISCOVERY THROUGH DATA ACCESS, CONSOLIDATION AND HARMONIZATION. *Neuro-Oncology*, **2019**, 21, ii76-ii76	1	78
199	HGG-22. CHARACTERIZING THE ROLE H3.3G34R MUTATION IN PEDIATRIC HIGH GRADE ASTROCYTOMA. *Neuro-Oncology*, **2019**, 21, ii91-ii91	1	78
198	LGG-07. CLINICAL FEATURES OF NON-CANONICAL MOLECULAR DRIVERS IN PLGG; AN UPDATE FORM THE INTERNATIONAL PLGG TASKFORCE. *Neuro-Oncology*, **2019**, 21, ii100-ii100	1	78
197	DIPG-36. CLINICAL, RADIOLOGICAL, AND HISTO-MOLECULAR CHARACTERISTICS OF DIFFUSE INTRINSIC PONTINE GLIOMA IN PATIENTS WHO SURVIVE LESS THAN 3 MONTHS FROM DIAGNOSIS: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. *Neuro-Oncology*, **2019**, 21, ii76-ii77	1	78
196	IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL REPLICATION REPAIR DEFICIENCY CONSORTIUM. *Neuro-Oncology*, **2019**, 21, ii96-ii97	1	78
195	LGG-01. BRAF V600E MUTANT OLIGODENDROGLIOMA-LIKE TUMORS WITH CHROMOSOMAL INSTABILITY IN ADOLESCENT AND YOUNG ADULT. *Neuro-Oncology*, **2019**, 21, ii98-ii98	1	78
194	HGG-18. ALTERNATIVE SPLICING OF NEUROFIBROMIN 1 IS ASSOCIATED WITH ELEVATED MAPK ACTIVITY AND POOR PROGNOSIS IN HIGH-GRADE GLIOMA. *Neuro-Oncology*, **2019**, 21, ii90-ii90	1	78
193	HGG-19. MOLECULAR ANALYSIS UNCOVERS 3 DISTINCT SUBGROUPS AND MULTIPLE TARGETABLE GENE FUSIONS IN INFANT GLIOMAS. *Neuro-Oncology*, **2019**, 21, ii90-ii91	1	78
192	DIPG-70. CLINICAL, RADIOLOGICAL, PATHOLOGICAL AND MOLECULAR CHARACTERISTICS OF CHILDREN . *Neuro-Oncology*, **2018**, 20, i63-i63	1	78
191	MEDU-04. AN OTX2-PAX GENE NETWORK REGULATES GROUP 3 MEDULLOBLASTOMA DIFFERENTIATION AND TUMOR GROWTH. *Neuro-Oncology*, **2019**, 21, ii103-ii104	1	78
190	DETAILED MOLECULAR CHARACTERISATION OF DIFFUSE INTRINSIC PONTINE GLIOMAS IDENTIFIES THREE MOLECULAR SUBGROUPS AND A NOVEL CANCER DRIVER, ACVR1. *Neuro-Oncology*, **2014**, 16, iii26-iii27	1	78
189	ATRT-33. ENABLING RAPID CLASSIFICATION OF ATRT WITH NANOSTRING NCOUNTER PLATFORM. *Neuro-Oncology*, **2020**, 22, iii282-iii282	1	78
188	MODL-25. REPLICATION REPAIR DEFICIENT MOUSE MODELS PROVIDE INSIGHT ON HYPERMUTANT BRAIN TUMOURS, MECHANISMS OF IMMUNE EVASION, AND COMBINATORIAL IMMUNOTHERAPY. *Neuro-Oncology*, **2020**, 22, iii416-iii416	1	78
187	DIPG-46. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW. *Neuro-Oncology*, **2020**, 22, iii295-iii296	1	78

186	LGG-13. THE CLINICAL AND MOLECULAR LANDSCAPE OF GLIOMAS IN ADOLESCENTS AND YOUNG ADULTS. *Neuro-Oncology*, **2020**, 22, iii368-iii368	1	78
185	LGG-19. SPINAL LOW-GRADE GLIOMAS IN CANADIAN CHILDREN: A MULTI-CENTRE RETROSPECTIVE REVIEW. *Neuro-Oncology*, **2020**, 22, iii369-iii370	1	78
184	ETMR-21. META-ANALYSIS OF PINEAL REGION TUMOURS DEMONSTRATES MOLECULAR SUBGROUPS WITH DISTINCT CLINICO-PATHOLOGICAL FEATURES: A CONSENSUS STUDY. *Neuro-Oncology*, **2020**, 22, iii327-iii327	1	78
183	LGG-34. CLINICAL AND MOLECULAR CHARACTERIZATION OF A MULTI-INSTITUTIONAL COHORT OF PEDIATRIC SPINAL CORD LOW-GRADE GLIOMAS. *Neuro-Oncology*, **2020**, 22, iii373-iii373	1	78
182	HGG-20. DIAGNOSTIC AND BIOLOGICAL ROLE OF METHYLATION PATTERNS IN REPLICATION REPAIR DEFICIENT HIGH GRADE GLIOMAS. *Neuro-Oncology*, **2020**, 22, iii347-iii348	1	78
181	LGG-50. INTEGRATED MOLECULAR AND CLINICAL ANALYSIS OF 1,000 PEDIATRIC LOW-GRADE GLIOMAS UNCOVERS NOVEL SUBGROUPS FOR CLINICAL RISK STRATIFICATION. *Neuro-Oncology*, **2020**, 22, iii375-iii376	1	78
180	DIPG-59. UPREGULATION OF PRENATAL PONTINE ID1 SIGNALING IN DIPG. *Neuro-Oncology*, **2020**, 22, iii298-iii299	1	78
179	PATH-14. GENETIC SUSCEPTIBILITY AND OUTCOMES OF PEDIATRIC, ADOLESCENT AND YOUNG ADULT IDH-MUTANT ASTROCYTOMAS. *Neuro-Oncology*, **2020**, 22, iii427-iii427	1	78
178	LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. *Neuro-Oncology*, **2020**, 22, iii377-iii377	1	78
177	ETMR-22. TITLE: DEFINING THE CLINICAL AND PROGNOSTIC LANDSCAPE OF EMBRYONAL TUMORS WITH MULTI-LAYERED ROSETTES (ETMRs), A RARE BRAIN TUMOR REGISTRY (RBTC) STUDY. *Neuro-Oncology*, **2020**, 22, iii327-iii328	1	78
176	HGG-39. ALTERNATIVE SPLICING OF NEUROFIBROMIN 1 IS ASSOCIATED WITH ELEVATED MAPK ACTIVITY AND POOR PROGNOSIS IN HIGH-GRADE GLIOMA. *Neuro-Oncology*, **2021**, 23, i25-i25	1	78
175	OMRT-8. Precision targeting of cellular pathways with complementary diagnostics. *Neuro-Oncology Advances*, **2021**, 3, ii8-ii8	0.9	78
174	LG-66CLINICAL AND TREATMENT FACTORS DETERMINING LONG-TERM OUTCOMES FOR ADULT SURVIVORS OF CHILDHOOD LOW-GRADE GLIOMA: A POPULATION-BASED STUDY. *Neuro-Oncology* , **2016**, 18, iii94.1-iii94	1	78
173	PNR-32UPDATE OF DIAGNOSTICS OF PRIMITIVE NEUROECTODERMAL TUMOURS OF THE CNS - NEUROPATHOLOGICAL RE-EVALUATION OF 99 CASES. *Neuro-Oncology*, **2016**, 18, iii13.1-iii13	1	78
172	LGG-16. PREDICTORS OF OUTCOME IN BRAF-V600E PEDIATRIC GLIOMAS TREATED WITH BRAF INHIBITORS: A REPORT FROM THE PLGG TASKFORCE. *Neuro-Oncology*, **2019**, 21, ii102-ii102	1	78
171	TMOD-10. REPLICATION REPAIR DEFICIENT MOUSE MODELS PROVIDE INSIGHT ON HYPERMUTANT BRAIN TUMOURS AND COMBINATIONAL IMMUNOTHERAPY. *Neuro-Oncology*, **2019**, 21, ii123-ii123	1	78
170	LGG-10. EPIGENETIC/GENETIC/MORPHOLOGIC ANALYSES REVEAL CLINICAL/PROGNOSTIC INSIGHT OF PEDIATRIC LOW GRADE GLIOMAS. *Neuro-Oncology*, **2018**, 20, i106-i106	1	78
169	ATRT-40. IMPACT OF MOLECULAR SUBTYPES ON TREATMENT OUTCOMES IN RHABDOID TUMORS - A REPORT FROM THE RARE TUMOR CONSORTIUM. *Neuro-Oncology*, **2018**, 20, i36-i36	1	78

168	DIPG-55. TARGETING SENESCENT CELLS WITH ABT-263 ENHANCES CELL DEATH INDUCED BY BMI1 INHIBITION AND IONIZING RADIATION IN DIPG. *Neuro-Oncology*, **2018**, 20, i60-i60	1	78
167	EPEN-31. SUBGROUP SPECIFIC LONG-TERM SURVIVAL AND NEUROCOGNITIVE OUTCOMES IN POSTERIOR FOSSA EPENDYMOMA (PFE). *Neuro-Oncology*, **2018**, 20, i79-i79	1	78
166	HGG-17. TUMOR MUTATIONAL BURDEN ANALYSIS OF PEDIATRIC TUMORS PROVIDES A DIAGNOSTIC TOOL FOR GERMLINE REPLICATION REPAIR DEFICIENCY AND PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITION. *Neuro-Oncology*, **2018**, 20, i92-i92	1	78
165	MBRS-62. REPRESSIVE CHROMATIN REMODELERS IN SHH-DRIVEN MEDULLOBLASTOMA. *Neuro-Oncology*, **2018**, 20, i141-i141	1	78
164	EAPH-06. HYPERMUTANT PEDIATRIC HIGH GRADE GLIOMAS ARE DRIVEN BY RAS/MAPK MUTATIONS AND RESPOND TO MEK INHIBITION. *Neuro-Oncology*, **2018**, 20, i66-i66	1	78
163	TBIO-30. MOLECULAR LANDSCAPE AND CLINICAL CORRELATIONS OF CNS SARCOMAS. *Neuro-Oncology*, **2018**, 20, i186-i186	1	78
162	LGG-49. MOLECULAR ALTERATIONS IN PREGNANT ADOLESCENT AND YOUNG ADULT WOMEN WITH GLIOMA. *Neuro-Oncology*, **2018**, 20, i115-i115	1	78
161	EMBR-12. IMPROVED DIAGNOSTIC ALGORITHM FOR DIFFERENTIAL DIAGNOSTICS OF CNS EMBRYONAL TUMORS (FORMER CNS-PNET) BY NEUROPATHOLOGICAL RE-EVALUATION OF 256 CASES AND CROSSVALIDATION BY METHYLATION CLASSIFICATION. *Neuro-Oncology*, **2018**, 20, i71-i71	1	78
160	LGG-59. REMARKABLE OBJECTIVE RESPONSE AND FAVORABLE SURVIVAL FOR BRAF-V600E CHILDHOOD LOW-GRADE GLIOMAS TO BRAF INHIBITORS COMPARED CONVENTIONAL CHEMOTHERAPY. *Neuro-Oncology*, **2018**, 20, i117-i117	1	78
159	DIPG-38. ID1 EXPRESSION CORRELATES WITH H3F3A K27M MUTATION AND EXTRA-PONTINE INVASION IN DIPG. *Neuro-Oncology*, **2018**, 20, i56-i56	1	78
158	EMBR-17. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOR CONSORTIUM. *Neuro-Oncology*, **2018**, 20, i72-i73	1	78
157	Phenotypic and genotypic characterisation of biallelic mismatch repair deficiency (BMMR-D) syndrome. *European Journal of Cancer*, **2015**, 51, 977-83	7.5	77
156	Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: A population-based study. *Cancer*, **2016**, 122, 1261-9	6.4	77
155	Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. *Acta Neuropathologica Communications*, **2016**, 4, 93	7.3	77
154	Pediatric low-grade gliomas: next biologically driven steps. *Neuro-Oncology*, **2018**, 20, 160-173	1	76
153	Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma. *Frontiers in Oncology*, **2015**, 5, 147	5.3	67
152	A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. *Journal of Experimental Medicine*, **2011**, 208, 689-702	16.6	65
151	Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups. *Clinical Cancer Research*, **2015**, 21, 184-92	12.9	63

150	The role of telomere maintenance in the spontaneous growth arrest of pediatric low-grade gliomas. *Neoplasia*, **2006**, 8, 136-42	6.4	61
149	Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. *Nature Medicine*, **2020**, 26, 720-731	50.5	60
148	Intellectual Outcome in Molecular Subgroups of Medulloblastoma. *Journal of Clinical Oncology*, **2016**, 34, 4161-4170	2.2	56
147	Pediatric low-grade glioma in the era of molecular diagnostics. *Acta Neuropathologica Communications*, **2020**, 8, 30	7.3	52
146	Lethal Disorder of Mitochondrial Fission Caused by Mutations in DNM1L. *Journal of Pediatrics*, **2016** , 171, 313-6.e1-2	3.6	52
145	cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. *Brain Pathology*, **2020**, 30, 863-866	6	51
144	High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan. *International Journal of Cancer*, **2016**, 138, 380-5	7.5	48
143	Tyrosine kinase expression in pediatric high grade astrocytoma. *Journal of Neuro-Oncology*, **2008**, 87, 247-53	4.8	47
142	Pediatric low-grade gliomas: implications of the biologic era. *Neuro-Oncology*, **2017**, 19, 750-761	1	47
141	Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma. *Pediatric Blood and Cancer*, **2016**, 63, 2038-41	3	43
140	ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents. *Cancer Discovery*, **2014**, 4, 1198-213	24.4	43
139	Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma. *Molecular Cancer Therapeutics*, **2015**, 14, 2560-8	6.1	37
138	cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. *Brain Pathology*, **2017** , 27, 851-852	6	36
137	Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. *Clinical Cancer Research*, **2015**, 21, 3750-8	12.9	35
136	Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome. *Brain Pathology*, **2017**, 27, 411-418	6	34
135	A comprehensive review of paediatric low-grade diffuse glioma: pathology, molecular genetics and treatment. *Brain Tumor Pathology*, **2017**, 34, 51-61	3.2	33
134	Reirradiation in patients with diffuse intrinsic pontine gliomas: The Canadian experience. *Pediatric Blood and Cancer*, **2018**, 65, e26988	3	33
133	Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. *Acta Neuropathologica*, **2014**, 128, 863-77	14.3	30

132	Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature. *Journal of Neuro-Oncology*, **2017**, 132, 155-162	4.8	29
131	H3 K27M mutations are extremely rare in posterior fossa group A ependymoma. *Childls Nervous System*, **2017**, 33, 1047-1051	1.7	29
130	Pediatric thalamic tumors in the MRI era: a Canadian perspective. *Childls Nervous System*, **2016**, 32, 269-80	1.7	29
129	Germline and somatic mutations in with diverse neurodevelopmental phenotypes. *Neurology: Genetics*, **2017**, 3, e199	3.8	28
128	Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. *Acta Neuropathologica*, **2020**, 139, 223-241	14.3	28
127	Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost. *Cancer*, **2019**, 125, 1867-1876	6.4	26
126	A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours. *European Journal of Cancer*, **2009**, 45, 2352-9	7.5	26
125	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. *JCO Precision Oncology*, **2020**, 4,	3.6	23
124	An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update. *Childls Nervous System*, **2016**, 32, 1789-97	1.7	22
123	Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas. *Cancer Cell*, **2020**, 37, 308-323.e12	24.3	21
122	Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. *Neuro-Oncology*, **2020**, 22, 773-784	1	21
121	Rasmussen's encephalitis: advances in management and patient outcomes. *Childls Nervous System*, **2016**, 32, 629-40	1.7	21
120	Identification of complex genomic rearrangements in cancers using CouGaR. *Genome Research*, **2017**, 27, 107-117	9.7	21
119	Targeting reduced mitochondrial DNA quantity as a therapeutic approach in pediatric high-grade gliomas. *Neuro-Oncology*, **2020**, 22, 139-151	1	21
118	The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease. *Journal of Neuro-Oncology*, **2017**, 132, 323-331	4.8	19
117	An update on the CNS manifestations of brain tumor polyposis syndromes. *Acta Neuropathologica*, **2020**, 139, 703-715	14.3	19
116	Massive CAG repeat expansion and somatic instability in maternally transmitted infantile spinocerebellar ataxia type 7. *JAMA Neurology*, **2015**, 72, 219-23	17.2	19
115	Cribriform neuroepithelial tumour: novel clinicopathological, ultrastructural and cytogenetic findings. *Acta Neuropathologica*, **2011**, 122, 511-4	14.3	19

114	Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children's Oncology Group (ACNS1221). *Journal of Clinical Oncology*, **2020**, 38, 223-231	2.2	19
113	Management and outcome of chordomas in the pediatric population: The Hospital for Sick Children experience and review of the literature. *Journal of Clinical Neuroscience*, **2016**, 34, 169-176	2.2	19
112	International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma. *Journal of Neuro-Oncology*, **2019**, 141, 253-263	4.8	19
111	A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma. *Oncotarget*, **2015**, 6, 2709-24	3.3	18
110	GLI2 is a potential therapeutic target in pediatric medulloblastoma. *Journal of Neuropathology and Experimental Neurology*, **2011**, 70, 430-7	3.1	17
109	CD271 Cells Are Diagnostic and Prognostic and Exhibit Elevated MAPK Activity in SHH Medulloblastoma. *Cancer Research*, **2018**, 78, 4745-4759	10.1	16
108	Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma. *Neuro-Oncology*, **2019**, 21, 547-557	1	16
107	Loss of p53 cooperates with K-ras activation to induce glioma formation in a region-independent manner. *Glia*, **2013**, 61, 1862-72	9	15
106	B7-H3 as a Prognostic Biomarker and Therapeutic Target in Pediatric central nervous system Tumors. *Translational Oncology*, **2020**, 13, 365-371	4.9	15
105	Prognostic relevance of miR-124-3p and its target TP53INP1 in pediatric ependymoma. *Genes Chromosomes and Cancer*, **2017**, 56, 639-650	5	14
104	Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. *Neuro-Oncology*, **2020**, 22, 1474-1483	1	14
103	Sustained Response to Targeted Therapy in a Patient With Disseminated Anaplastic Pleomorphic Xanthoastrocytoma. *Journal of Pediatric Hematology/Oncology*, **2018**, 40, 478-482	1.2	14
102	MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry. *Neuro-Oncology*, **2020**, 22, 1647-1657	1	12
101	DNA methylation signature is prognostic of choroid plexus tumor aggressiveness. *Clinical Epigenetics*, **2019**, 11, 117	7.7	12
100	Synchronous glioblastoma and medulloblastoma in a child with mismatch repair mutation. *Childls Nervous System*, **2016**, 32, 553-7	1.7	11
99	Transcriptional repressor REST drives lineage stage-specific chromatin compaction at and increases AKT activation in a mouse model of medulloblastoma. *Science Signaling*, **2019**, 12,	8.8	11
98	JPO2/CDCA7L and LEDGF/p75 Are Novel Mediators of PI3K/AKT Signaling and Aggressive Phenotypes in Medulloblastoma. *Cancer Research*, **2016**, 76, 2802-12	10.1	11
97	Hemorrhagic presentations of cerebellar pilocytic astrocytomas in children resulting in death: report of 2 cases. *Journal of Neurosurgery: Pediatrics*, **2016**, 17, 446-52	2.1	11

96	Viruses and human brain tumors: cytomegalovirus enters the fray. *Journal of Clinical Investigation*, **2011**, 121, 3831-3	15.9	11
95	Diffuse midline glioma: review of epigenetics. *Journal of Neuro-Oncology*, **2020**, 150, 27-34	4.8	11
94	Recessive mutations in muscle-specific isoforms of FXR1 cause congenital multi-minicore myopathy. *Nature Communications*, **2019**, 10, 797	17.4	10
93	Medulloblastoma Arises from the Persistence of a Rare and Transient Sox2 Granule Neuron Precursor. *Cell Reports*, **2020**, 31, 107511	10.6	10
92	Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG. *Cell Reports*, **2020**, 33, 108286	10.6	10
91	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. *Journal of Clinical Oncology*, **2021**, 39, 2779-2790	2.2	10
90	Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. *Acta Neuropathologica*, **2021**, 141, 771-785	14.3	9
89	Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples. *Journal of Neuropathology and Experimental Neurology*, **2020**, 79, 437-447	3.1	8
88	Differential transformation capacity of neuro-glial progenitors during development. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 14378-83	11.5	8
87	An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate. *Nature Communications*, **2020**, 11, 3627	17.4	8
86	Epigenetic activation of a RAS/MYC axis in H3.3K27M-driven cancer. *Nature Communications*, **2020**, 11, 6216	17.4	8
85	Germline-driven replication repair-deficient high-grade gliomas exhibit unique hypomethylation patterns. *Acta Neuropathologica*, **2020**, 140, 765-776	14.3	8
84	Sarcoma Subgrouping by Detection of Fusion Transcripts Using NanoString nCounter Technology. *Pediatric and Developmental Pathology*, **2019**, 22, 205-213	2.2	7
83	ACNS1221: A phase II study for the treatment of non metastatic desmoplastic medulloblastoma in children less than 4 years of age A report from the Children Oncology Group.. *Journal of Clinical Oncology*, **2017**, 35, 10505-10505	2.2	7
82	Cancer proteome and metabolite changes linked to SHMT2. *PLoS ONE*, **2020**, 15, e0237981	3.7	7
81	MEDU-34. PILOT STUDY OF A SURGERY AND CHEMOTHERAPY-ONLY APPROACH IN THE UPFRONT THERAPY OF CHILDREN WITH WNT-POSITIVE STANDARD RISK MEDULLOBLASTOMA. *Neuro-Oncology*, **2019**, 21, ii110-ii110	1	7
80	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. *Journal of Clinical Oncology*, **2021**, 39, 807-821	2.2	7
79	Two different STAT1 gain-of-function mutations lead to diverse IFN- mediated gene expression. *Npj Genomic Medicine*, **2018**, 3, 23	6.2	7

78	Local FK506 drug delivery enhances nerve regeneration through fresh, unprocessed peripheral nerve allografts. *Experimental Neurology*, **2021**, 341, 113680	5.7	7
77	Mitochondrial POLG related disorder presenting prenatally with fetal cerebellar growth arrest. *Metabolic Brain Disease*, **2018**, 33, 1369-1373	3.9	6
76	Embryonal tumor with multilayered rosettes, C19MC-altered: Report of an extremely rare malignant pediatric central nervous system neoplasm. *SAGE Open Medical Case Reports*, **2017**, 5, 2050313X17745208	0.7	6
75	Multiplexed Digital Detection of B-Cell Acute Lymphoblastic Leukemia Fusion Transcripts Using the NanoString nCounter System. *Journal of Molecular Diagnostics*, **2020**, 22, 72-80	5.1	6
74	Acute MR-Guided High-Intensity Focused Ultrasound Lesion Assessment Using Diffusion-Weighted Imaging and Histological Analysis. *Frontiers in Neurology*, **2019**, 10, 1069	4.1	6
73	Noncompaction cardiomyopathy in an infant with Walker-Warburg syndrome. *American Journal of Medical Genetics, Part A*, **2017**, 173, 3082-3086	2.5	5
72	Re-irradiation for children with recurrent medulloblastoma in Toronto, Canada: a 20-year experience. *Journal of Neuro-Oncology*, **2019**, 145, 107-114	4.8	5
71	Repeat irradiation for children with supratentorial high-grade glioma. *Pediatric Blood and Cancer*, **2019**, 66, e27881	3	5
70	BRAF V600E mutant oligodendroglioma-like tumors with chromosomal instability in adolescents and young adults. *Brain Pathology*, **2020**, 30, 515-523	6	5
69	Radiomics of Pediatric Low-Grade Gliomas: Toward a Pretherapeutic Differentiation of Mutated and -Fused Tumors. *American Journal of Neuroradiology*, **2021**, 42, 759-765	4.4	5
68	A preclinical study demonstrating the efficacy of nilotinib in inhibiting the growth of pediatric high-grade glioma. *Journal of Neuro-Oncology*, **2015**, 122, 471-80	4.8	4
67	Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin. *Pediatric Neurology*, **2015**, 53, 238-242.e1	2.9	4
66	Pontine gliomas a 10-year population-based study: a report from The Canadian Paediatric Brain Tumour Consortium (CPBTC). *Journal of Neuro-Oncology*, **2020**, 149, 45-54	4.8	4
65	Diffuse intrinsic pontine glioma ventricular peritoneal shunt metastasis: a case report and literature review. *Childls Nervous System*, **2019**, 35, 861-864	1.7	3
64	Ongoing issues with the management of children with Constitutional Mismatch Repair Deficiency syndrome. *European Journal of Medical Genetics*, **2019**, 62, 103706	2.6	3
63	Relationship of BRAF V600E and associated secondary mutations on survival rate and response to conventional therapies in childhood low-grade glioma.. *Journal of Clinical Oncology*, **2016**, 34, 10509-10509	2.2	3
62	Clinical and molecular characterization of a multi-institutional cohort of pediatric spinal cord low-grade gliomas. *Neuro-Oncology Advances*, **2020**, 2, vdaa103	0.9	3
61	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. *Neuro-Oncology*, **2021**, 23, 1597-1611	1	3

60	Pearls & Oy-sters: Fatal brain edema is a rare complication of severe CACNA1A-related disorder. *Neurology*, **2020**, 94, 631-634	6.5	3
59	EMBR-15. DIAGNOSTIC RE-EVALUATION AND POOLED CLINICAL DATA ANALYSIS OF PATIENTS WITH PREVIOUS DIAGNOSIS OF CNS-PNET. *Neuro-Oncology*, **2018**, 20, i72-i72	1	2
58	Weekly vinblastine in chemotherapy-naive children with unresectable or progressive low grade glioma: A Canadian cooperative study.. *Journal of Clinical Oncology*, **2013**, 31, 10029-10029	2.2	2
57	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency.. *Nature Medicine*, **2022**,	50.5	2
56	MetaFusion: A high-confidence metacaller for filtering and prioritizing RNA-seq gene fusion candidates. *Bioinformatics*, **2021**,	7.2	2
55	Detecting Stem Cell Marker Expression Using the NanoString nCounter System. *Methods in Molecular Biology*, **2019**, 1869, 57-67	1.4	2
54	MBCL-08. MOLECULAR CHARACTERIZATION OF NODULAR DESMOPLASTIC MEDULLOBLASTOMAS IN YOUNG CHILDREN TREATED ON ACNS1221. A REPORT FROM THE CHILDREN ONCOLOGY GROUP. *Neuro-Oncology*, **2018**, 20, i118-i119	1	2
53	Genetic alterations in paediatric high grade astrocytomas. *Diagnostic Histopathology*, **2014**, 20, 84-90	0.7	1
52	BT-02 * FUNCTIONALLY-DEFINED THERAPEUTIC TARGETS IN DIFFUSE INTRINSIC PONTINE GLIOMA. *Neuro-Oncology*, **2015**, 17, iii3-iii3	1	1
51	Reply to J.C. Lindsey et al. *Journal of Clinical Oncology*, **2011**, 29, e347-e347	2.2	1
50	Investigating Urinary Circular RNA Biomarkers for Improved Detection of Renal Cell Carcinoma.. *Frontiers in Oncology*, **2021**, 11, 814228	5.3	1
49	Outcome of neurofibromatosis type 1 patients treated with first line vinblastine for optic pathway gliomas: A Canadian multicenter study.. *Journal of Clinical Oncology*, **2015**, 33, 2019-2019	2.2	1
48	Apparent Lack of Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8 T Cells in Langerhans Cell Histiocytosis. *Frontiers in Immunology*, **2019**, 10, 3045	8.4	1
47	MBCL-25. PILOT STUDY OF A SURGERY AND CHEMOTHERAPY-ONLY APPROACH IN THE UPFRONT THERAPY OF CHILDREN WITH WNT-POSITIVE STANDARD RISK MEDULLOBLASTOMA: UPDATED OUTCOMES. *Neuro-Oncology*, **2020**, 22, iii393-iii394	1	1
46	LGG-25. A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. TRAM-01. *Neuro-Oncology*, **2020**, 22, iii371-iii371	1	1
45	IMMU-18. FAVORABLE OUTCOME IN REPLICATION REPAIR DEFICIENT HYPERMUTANT BRAIN TUMORS TO IMMUNE CHECKPOINT INHIBITION: AN INTERNATIONAL RRD CONSORTIUM REGISTRY STUDY. *Neuro-Oncology*, **2020**, 22, iii363-iii363	1	1
44	MBRS-54. POOR SURVIVAL IN REPLICATION REPAIR DEFICIENT HYPERMUTANT MEDULLOBLASTOMA AND CNS EMBRYONAL TUMORS: A REPORT FROM THE INTERNATIONAL RRD CONSORTIUM. *Neuro-Oncology*, **2020**, 22, iii407-iii407	1	1
43	Modeling DIPG in the mouse brainstem. *Neuro-Oncology*, **2020**, 22, 307-308	1	1

42	Indolent course of brainstem tumors with K27M-H3.3 mutation. *Pediatric Blood and Cancer*, **2020**, 67, e28102	3	1
41	Characteristics of Patients ≤10 Years of Age with Diffuse Intrinsic Pontine Glioma: A Report from the International DIPG Registry. *Neuro-Oncology*, **2021**,	1	1
40	Salvage chemotherapy after failure of targeted therapy in a child with BRAF V600E low-grade glioma. *Pediatric Blood and Cancer*, **2021**, 68, e28561	3	1
39	IMMU-25. PROGRAMMED CELL DEATH-LIGAND 1 (PD-L1) IS NOT EXPRESSED IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) TUMOR CELLS. *Neuro-Oncology*, **2018**, 20, vi126-vi126	1	1
38	LGG-60. THE GENETIC LANDSCAPE OF PEDIATRIC LOW-GRADE GLIOMAS: INCIDENCE, PROGNOSIS AND RESPONSE TO THERAPY. *Neuro-Oncology*, **2018**, 20, i117-i117	1	1
37	DIPG-69. CHARACTERISTICS OF PATIENTS ≤10 YEARS OF AGE WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. *Neuro-Oncology*, **2018**, 20, i63-i63	1	1
36	Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. *The Lancet Child and Adolescent Health*, **2021**, 5, 800-813	14.5	1
35	Medulloblastoma: WHO 2021 and Beyond.. *Pediatric and Developmental Pathology*, **2022**, 25, 23-33	2.2	1
34	Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study.. *JCO Precision Oncology*, **2022**, 6, e2100286	3.6	1
33	Building the ecosystem for pediatric neuro-oncology care in Pakistan: Results of a 7-year long twinning program between Canada and Pakistan.. *Pediatric Blood and Cancer*, **2022**, e29726	3	1
32	IMMU-17. Comprehensive immunological gene expression profiling of pediatric brain tumors. *Neuro-Oncology*, **2022**, 24, i85-i85	1	1
31	LG-19IMMUNOHISTOCHEMISTRY IS HIGHLY SENSITIVE AND SPECIFIC FOR THE DETECTION OF BRAF V600E STATUS IN PEDIATRIC LOW-GRADE GLIOMA. *Neuro-Oncology*, **2016**, 18, iii82.3-iii82	1	0
30	Splicing is an alternate oncogenic pathway activation mechanism in glioma.. *Nature Communications* , **2022**, 13, 588	17.4	0
29	Pediatric Glial Tumors. *Pediatric and Developmental Pathology*, **2021**, 10935266211009101	2.2	0
28	Re-irradiation with concurrent BRAF and MEK inhibitor therapy. *Pediatric Blood and Cancer*, **2021**, 68, e28838	3	0
27	Upfront Adjuvant Immunotherapy of Replication Repair-Deficient Pediatric Glioblastoma With Chemoradiation-Sparing Approach.. *JCO Precision Oncology*, **2021**, 5, 1426-1431	3.6	0
26	Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma. *Pediatric Blood and Cancer*, **2022**, 69, e29316	3	0
25	SYST-04. TRAM-01: A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. *Neuro-Oncology Advances*, **2021**, 3, iv9-iv9	0.9	0

24	Ependymal Tumors.. *Pediatric and Developmental Pathology*, **2022**, 25, 59-67	2.2	0
23	IMMU-13. Dual CTLA4/ PD-1 blockade improves survival for replication-repair deficient high-grade gliomas failing single agent PD-1 inhibition: An IRRDC study. *Neuro-Oncology*, **2022**, 24, i84-i84	1	0
22	Giant choroid plexus cysts with calvarial erosion: a case report and literature review. *Childls Nervous System*, **2021**, 37, 2381-2385	1.7	
21	The neuroprotective effects of anti-cd18 therapy after transient global ischemic brain injury in the mouse. *Canadian Journal of Anaesthesia*, **2006**, 53, 26428-26428	3	
20	TAMI-29. MULTIFACTORIAL UPREGULATION OF ID1 DRIVES DIPG INVASIVENESS AND IS THERAPEUTICALLY TARGETABLE. *Neuro-Oncology*, **2020**, 22, ii219-ii219	1	
19	NIMG-31. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW. *Neuro-Oncology*, **2020**, 22, ii154-ii154	1	
18	CTNI-24. A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. TRAM-01. *Neuro-Oncology*, **2020**, 22, ii47-ii47	1	
17	DDRE-06. CELLULAR STRESS RESPONSE IN DIPG THERAPY. *Neuro-Oncology*, **2020**, 22, ii62-ii62	1	
16	Germline predisposition to glial neoplasms in children and young adults: A narrative review. *Glioma (Mumbai, India)*, **2021**, 4, 68	0.3	
15	Clinical and economic impact of molecular testing for BRAF fusion in pediatric low-grade Glioma.. *BMC Pediatrics*, **2022**, 22, 13	2.6	
14	EXTH-30. HARNESSING CELLULAR STRESS FOR IMMUNE TARGETING OF DIPGS. *Neuro-Oncology*, **2021**, 23, vi169-vi170	1	
13	CTNI-06. TRAM-01: A PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK/ERK PATHWAY. *Neuro-Oncology*, **2021**, 23, vi59-vi60	1	
12	INNV-43. MORE THAN WHAT MEETS THE EYE: ETMR AN UNDER RECOGNISED ATYPICAL BRAINSTEM PRIMARY. A RARE BRAIN TUMOR CONSORTIUM (RBTC) STUDY. *Neuro-Oncology*, **2021**, 23, vi114-vi115	1	
11	Re-irradiation for relapsed paediatric ependymoma.. *Journal of Clinical Oncology*, **2016**, 34, 10565-10565	2.2	
10	Imaging of metastatic medulloblastoma in the molecular era.. *Journal of Clinical Oncology*, **2016**, 34, e22003-e22003	2.2	
9	Molecular alterations to predict survival and response to chemotherapy of pediatric low-grade glioma.. *Journal of Clinical Oncology*, **2017**, 35, 10503-10503	2.2	
8	A Practical Approach to the Evaluation and Diagnosis of Pediatric CNS Tumors. *Pediatric and Developmental Pathology*, **2021**, 10935266211007022	2.2	
7	Clinical Neuropathological Conference: There's a Child in All of Us. *Canadian Journal of Neurological Sciences*,1-5	1	

6	Longitudinal Assessment of Enhancing Foci of Abnormal Signal Intensity in Neurofibromatosis Type 1. *American Journal of Neuroradiology*, **2021**, 42, 766-773	4.4
5	The diverse landscape of histone-mutant pediatric high-grade gliomas: A narrative review. *Glioma (Mumbai, India)*, **2022**, 5, 5	0.3
4	EPCO-16. ONCOHISTONE INTERACTOME PROFILING UNCOVERS MECHANISMS OF CHROMATIN DISRUPTION AND IDENTIFIES POTENTIAL THERAPEUTIC TARGETS IN PEDIATRIC HIGH-GRADE GLIOMA. *Neuro-Oncology*, **2021**, 23, vi5-vi5	1
3	A novel central nervous system embryonal tumor successfully treated with multi-modal therapy highlights limitation of methylation-based tumor classification.. *Pediatric Blood and Cancer*, **2021**, e29520	2
2	LGG-41. The clinical and molecular landscape of gliomas in adolescents and young adults. *Neuro-Oncology*, **2022**, 24, i97-i97	1
1	HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. *Neuro-Oncology*, **2022**, 24, i61-i62	1